SI0915701T1 - Fast-dissolving galanthamine hydrobromide tablet - Google Patents

Fast-dissolving galanthamine hydrobromide tablet

Info

Publication number
SI0915701T1
SI0915701T1 SI9730690T SI9730690T SI0915701T1 SI 0915701 T1 SI0915701 T1 SI 0915701T1 SI 9730690 T SI9730690 T SI 9730690T SI 9730690 T SI9730690 T SI 9730690T SI 0915701 T1 SI0915701 T1 SI 0915701T1
Authority
SI
Slovenia
Prior art keywords
fast
galanthamine hydrobromide
hydrobromide tablet
dissolving
dissolving galanthamine
Prior art date
Application number
SI9730690T
Other languages
English (en)
Slovenian (sl)
Inventor
Paul Marie Victor Gilis
Conde Valentin Florent Victor De
Original Assignee
Jansen Pharmaceutica N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jansen Pharmaceutica N.V. filed Critical Jansen Pharmaceutica N.V.
Publication of SI0915701T1 publication Critical patent/SI0915701T1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SI9730690T 1996-06-14 1997-06-06 Fast-dissolving galanthamine hydrobromide tablet SI0915701T1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP96201676 1996-06-14
PCT/EP1997/002986 WO1997047304A1 (en) 1996-06-14 1997-06-06 Fast-dissolving galanthamine hydrobromide tablet
EP97927159A EP0915701B1 (en) 1996-06-14 1997-06-06 Fast-dissolving galanthamine hydrobromide tablet

Publications (1)

Publication Number Publication Date
SI0915701T1 true SI0915701T1 (en) 2005-06-30

Family

ID=8224084

Family Applications (1)

Application Number Title Priority Date Filing Date
SI9730690T SI0915701T1 (en) 1996-06-14 1997-06-06 Fast-dissolving galanthamine hydrobromide tablet

Country Status (33)

Country Link
US (2) US6099863A (cs)
EP (1) EP0915701B1 (cs)
JP (1) JP4172820B2 (cs)
KR (1) KR100358676B1 (cs)
CN (1) CN1102390C (cs)
AR (2) AR008237A1 (cs)
AT (1) ATE285777T1 (cs)
AU (1) AU726212B2 (cs)
BG (1) BG64168B1 (cs)
BR (1) BR9709729A (cs)
CA (1) CA2257431C (cs)
CZ (1) CZ295226B6 (cs)
DE (1) DE69732113T2 (cs)
DK (1) DK0915701T3 (cs)
EA (1) EA001193B1 (cs)
EE (1) EE03337B1 (cs)
ES (1) ES2235234T3 (cs)
HK (1) HK1019703A1 (cs)
HR (1) HRP970321B1 (cs)
ID (1) ID17088A (cs)
IL (1) IL127519A (cs)
MY (1) MY121669A (cs)
NO (1) NO322892B1 (cs)
NZ (1) NZ333280A (cs)
PL (1) PL189329B1 (cs)
PT (1) PT915701E (cs)
SI (1) SI0915701T1 (cs)
SK (1) SK284620B6 (cs)
TR (1) TR199802592T2 (cs)
TW (1) TW506836B (cs)
UA (1) UA62930C2 (cs)
WO (1) WO1997047304A1 (cs)
ZA (1) ZA975281B (cs)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6440457B1 (en) * 1993-05-27 2002-08-27 Alza Corporation Method of administering antidepressant dosage form
TW506836B (en) * 1996-06-14 2002-10-21 Janssen Pharmaceutica Nv Fast-dissolving galanthamine hydrobromide tablet
US8071128B2 (en) 1996-06-14 2011-12-06 Kyowa Hakko Kirin Co., Ltd. Intrabuccally rapidly disintegrating tablet and a production method of the tablets
CZ301658B6 (cs) 1998-12-24 2010-05-19 Janssen Pharmaceutica N. V. Prostredky s rízeným uvolnováním galantaminu
US20050063998A1 (en) * 1999-10-26 2005-03-24 Francois Marc Karel Jozef Oral solution containing galantamine and a sweetening agent
US6627223B2 (en) 2000-02-11 2003-09-30 Eurand Pharmaceuticals Ltd. Timed pulsatile drug delivery systems
EP1284729A4 (en) * 2000-04-13 2007-12-19 Mayo Foundation REDUCTION AGENTS OF A (BETA) 42
SE521512C2 (sv) * 2001-06-25 2003-11-11 Niconovum Ab Anordning för administrering av en substans till främre delen av en individs munhåla
US6500454B1 (en) * 2001-10-04 2002-12-31 Eurand Pharmaceuticals Ltd. Timed, sustained release systems for propranolol
US9358214B2 (en) 2001-10-04 2016-06-07 Adare Pharmaceuticals, Inc. Timed, sustained release systems for propranolol
DE10235556A1 (de) * 2002-08-03 2004-02-19 Hf Arzneimittelforschung Gmbh Medikament und Verfahren zur Verringerung des Alkohol- und/oder Tabakkonsums
US20040097484A1 (en) * 2002-11-14 2004-05-20 Marc Cantillion Once a day galantamine pharmaceutical compositions and methods of use
DE60313216T2 (de) * 2002-12-20 2008-01-03 Niconovum Ab Chemisch und physikalisch stabiles teilchenförmiges material enthaltend nikotin und microcrystalline cellulose
US8367111B2 (en) 2002-12-31 2013-02-05 Aptalis Pharmatech, Inc. Extended release dosage forms of propranolol hydrochloride
EP1603548A4 (en) * 2003-02-05 2007-10-10 Myriad Genetics Inc COMPOSITION AND METHOD FOR TREATING NEURODEGENERATIVE DISORDERS
US7521481B2 (en) 2003-02-27 2009-04-21 Mclaurin Joanne Methods of preventing, treating and diagnosing disorders of protein aggregation
DE10338544B4 (de) * 2003-08-19 2017-08-31 Janssen Pharmaceutica N.V. Buccale Formulierungen des Galanthamins und deren Anwendungen
CN1871018B (zh) * 2003-08-26 2011-11-02 夏尔控股公司 包含镧化合物的药物制剂
US20050143350A1 (en) * 2003-11-19 2005-06-30 Seed John C. Combination drug therapy to treat obesity
WO2005051489A2 (en) * 2003-11-28 2005-06-09 Ranbaxy Laboratories Limited Fast dissolving solid oral dosage forms of galanthamine
EP1763337A2 (en) * 2003-12-31 2007-03-21 Actavis Group HF Immediate, controlled and sustained release formulations of galanthamine
US20050142193A1 (en) * 2003-12-31 2005-06-30 Lijuan Tang Galantamine formulations
EP2340813A1 (en) * 2003-12-31 2011-07-06 Actavis Group PTC ehf. Solid dosage formulations of galantamine
WO2006020852A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
WO2006020850A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
CA2618985A1 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
US8747895B2 (en) 2004-09-13 2014-06-10 Aptalis Pharmatech, Inc. Orally disintegrating tablets of atomoxetine
US7888346B2 (en) * 2004-09-24 2011-02-15 Universtiy of Maryland, Baltimore Method of treating organophosphorous poisoning
US9884014B2 (en) 2004-10-12 2018-02-06 Adare Pharmaceuticals, Inc. Taste-masked pharmaceutical compositions
NZ728442A (en) 2004-10-21 2018-05-25 Adare Pharmaceuticals Inc Taste-masked pharmaceutical compositions with gastrosoluble pore-formers
AU2005308575A1 (en) * 2004-11-23 2006-06-01 Warner-Lambert Company Llc 7-(2h-pyrazol-3-yl)-3, 5-dihyroxy-heptanoic acid derivatives as HMG Co-A reductase inhibitors for the treatment of lipidemia
US20080145422A1 (en) * 2005-02-10 2008-06-19 Roxane Laboratories, Inc. Galantamine tablet formulation
US9161918B2 (en) 2005-05-02 2015-10-20 Adare Pharmaceuticals, Inc. Timed, pulsatile release systems
GB0516604D0 (en) * 2005-08-12 2005-09-21 Sandoz Ag Rapidly dispersing/disintegrating compositions
US8168219B2 (en) * 2005-11-30 2012-05-01 Isp Investments Inc. Synergistic binder composition, method for making same, and tablets of an active and said binder having advantageous hardness and friability
JP5694645B2 (ja) 2006-03-16 2015-04-01 ニコノヴァム エービーＮｉｃｏｎｏｖｕｍ Ａｂ 改善された嗅ぎたばこ組成物
NZ703464A (en) * 2006-04-26 2016-05-27 Alphapharm Pty Ltd Controlled release formulations comprising uncoated discrete unit(s) and an extended release matrix
GB0612540D0 (en) * 2006-06-23 2006-08-02 Novartis Ag Galenical formulations of organic compounds
WO2008008120A1 (en) * 2006-07-14 2008-01-17 Fmc Corporation Solid form
CN100438917C (zh) * 2006-07-20 2008-12-03 山东聊城阿华制药有限公司 一种微晶纤维素乳糖的制备方法
WO2008062426A2 (en) * 2006-08-02 2008-05-29 Emcure Pharmaceuticals Limited Formulation of benzazepine derivatives
CA2667553A1 (en) 2006-10-27 2008-05-02 Medivation Neurology, Inc. Methods and combination therapies for treating alzheimer's disease
US20080311162A1 (en) * 2007-05-16 2008-12-18 Olivia Darmuzey Solid form
PE20091156A1 (es) * 2007-12-17 2009-09-03 Astrazeneca Ab Sales de (3-{[[3-(6-amino-2-butoxi-8-oxo-7,8-dihidro-9h-purin-9-il)propil](3-morfolin-4-ilpropil)amino]metil}fenil)acetato de metilo
EP2116232B1 (de) 2008-05-09 2012-02-15 Ratiopharm GmbH Galanthaminhaltiges Arzneimittel mit kontrollierter Freisetzung
ES2668203T3 (es) 2009-12-02 2018-05-17 Adare Pharmaceuticals S.R.L. Microcápsulas de fexofenadina y composiciones que las contienen
WO2011151359A1 (en) 2010-06-02 2011-12-08 Noscira, S.A. Combined treatment with a cholinesterase inhibitor and a thiadiazolidinedione derivative
JP5656258B2 (ja) * 2011-03-09 2015-01-21 塩野義製薬株式会社 ガランタミンを含有する口腔内崩壊錠剤
AU2014307803A1 (en) 2013-08-16 2016-03-10 Universiteit Maastricht Treatment of cognitive impairment with PDE4 inhibitor
CN106822008A (zh) * 2017-01-11 2017-06-13 江苏艾兰得营养品有限公司 一种维生素d速溶制剂及其制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3506276C1 (de) * 1985-02-22 1986-04-24 Meggle Milchindustrie Gmbh & Co Kg, 8094 Reitmehring Direkttablettiermittel
US4663318A (en) * 1986-01-15 1987-05-05 Bonnie Davis Method of treating Alzheimer's disease
US6150354A (en) * 1987-01-15 2000-11-21 Bonnie Davis Compounds for the treatment of Alzheimer's disease
US5336675A (en) * 1991-05-14 1994-08-09 Ernir Snorrason Method of treating mania in humans
ES2134215T3 (es) * 1991-05-14 1999-10-01 Ernir Snorrason Tratamiento de sindromes de fatiga con inhibidores de colinesterasa.
TW506836B (en) * 1996-06-14 2002-10-21 Janssen Pharmaceutica Nv Fast-dissolving galanthamine hydrobromide tablet

Also Published As

Publication number Publication date
EP0915701A1 (en) 1999-05-19
CA2257431C (en) 2001-11-20
IL127519A (en) 2002-07-25
PL330431A1 (en) 1999-05-10
ES2235234T3 (es) 2005-07-01
TR199802592T2 (xx) 1999-03-22
JP2000511918A (ja) 2000-09-12
NZ333280A (en) 1999-09-29
ATE285777T1 (de) 2005-01-15
KR20000015851A (ko) 2000-03-15
EA199900026A1 (ru) 1999-06-24
US6358527B1 (en) 2002-03-19
SK284620B6 (sk) 2005-07-01
DE69732113D1 (de) 2005-02-03
SK169698A3 (en) 1999-10-08
HK1019703A1 (en) 2000-02-25
HRP970321B1 (en) 2001-12-31
NO985815L (no) 1998-12-11
CZ295226B6 (cs) 2005-06-15
HRP970321A2 (en) 1998-04-30
AR070670A2 (es) 2010-04-28
DE69732113T2 (de) 2005-12-08
TW506836B (en) 2002-10-21
PT915701E (pt) 2005-05-31
NO322892B1 (no) 2006-12-18
CN1102390C (zh) 2003-03-05
AU726212B2 (en) 2000-11-02
MY121669A (en) 2006-02-28
BR9709729A (pt) 1999-08-10
AU3174397A (en) 1998-01-07
PL189329B1 (pl) 2005-07-29
EE03337B1 (et) 2001-02-15
UA62930C2 (uk) 2004-01-15
CZ403498A3 (cs) 1999-03-17
ID17088A (id) 1997-12-04
EP0915701B1 (en) 2004-12-29
CN1222077A (zh) 1999-07-07
BG102991A (en) 1999-08-31
WO1997047304A1 (en) 1997-12-18
BG64168B1 (bg) 2004-03-31
DK0915701T3 (da) 2005-04-25
CA2257431A1 (en) 1997-12-18
EA001193B1 (ru) 2000-12-25
ZA975281B (en) 1998-12-14
KR100358676B1 (ko) 2003-02-17
IL127519A0 (en) 1999-10-28
JP4172820B2 (ja) 2008-10-29
AR008237A1 (es) 1999-12-29
NO985815D0 (no) 1998-12-11
US6099863A (en) 2000-08-08

Similar Documents

Publication Publication Date Title
IL127519A0 (en) Fast-dissolving galanthamine hydrobromide tablet
HK1018776A1 (en) Muscarinic antagonists
SG50002A1 (en) Pyrido-fused thienyl- and furanyl-oxazolidinones
PL336154A1 (en) Analgesic combination
AU132520S (en) Tablet
AU133610S (en) Tablet
HUP9903476A3 (en) Fast-dissolving galanthamine hydrobromide tablet
EP0906754A4 (en) S1452 QUICK RELEASE TABLETS
TW539084U (en) Sanitary fitting
CA79133S (en) Carrel
CA79131S (en) Carrel
CA80217S (en) Tablet
CA80449S (en) Tablet
CA80450S (en) Tablet
AU129688S (en) Base for bathing area
GB9613095D0 (en) Therapeutic piperidines
PL104209U1 (en) Well barrier
GB9605234D0 (en) Pharmaceutical tablet
GB9600037D0 (en) Adjustable packer
PL104626U1 (en) Special event coupon-book
AU128904S (en) Bathroom fitting set
GB9622757D0 (en) Cot barrier
AU131340S (en) Barrier
GB9607731D0 (en) Barrier
ZA967065B (en) Barrier